HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials.

Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials Fred M. Kusumoto, MD, FHRS (Chair), Hugh Calkins, MD, FHRS (Chair), John Boehmer, MD, Alfred E. Buxton, MD,* Mina K. Chung, MD, FHRS, Michael R. Gold, MD, PhD, FHRS, Stefan H. Hohnloser, MD, FHRS, Julia Indik, MD, PhD, FHRS, Richard Lee, MD, MBA, Mandeep R. Mehra, MD,* Venu Menon, MD, Richard L. Page, MD, FHRS, Win-Kuang Shen, MD,* David J. Slotwiner, MD, Lynne Warner Stevenson, MD, Paul D. Varosy, MD, FHRS, Lisa Welikovitch, MD From Mayo Clinic Jacksonville, Jacksonville, Florida, John Hopkins Hospital, Baltimore, Maryland, Pennsylvania State Hershey Medical Center, Hershey, Pennsylvania, Beth Israel Deaconess Medical Center, Boston, Massachusetts, Cleveland Clinic, Cleveland, Ohio, Medical University of South Carolina, Charleston, South Carolina, J.W. Goethe University, Frankfurt, Germany, University of Arizona, Sarver Heart Center, Tucson, Arizona, St. Louis University, St. Louis, Missouri, Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts, Cleveland Clinic, Cleveland, Ohio, University of Wisconsin School of Medicine and Public Health, Mayo Clinic College of Medicine, Phoenix, Arizona, Hofstra North Shore – Long Island Jewish School of Medicine, Cardiac Electrophysiology Lab, NewHyde Park, New York, Brigham&Women’s Hospital, Boston, Massachusetts, VA Eastern Colorado Health Care System, Cardiology, Denver, Colorado, and Department of Cardiac Services, University of Calgary, Alberta, Canada.